March 28 (Reuters) - Roivant Sciences Ltd ROIV.O:
NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES POSITIVE PHASE 3 VALOR TRIAL RESULTS OF BREPOCITINIB IN DERMATOMYOSITIS
ROIVANT SCIENCES LTD - FDA GRANTS PRIORITY REVIEW TO BREPOCITINIB NDA WITH PDUFA DATE IN Q3 2026